Stent with coatings containing self-assembled monolayers

Inactive Publication Date: 2006-08-10
ABBOTT CARDIOVASCULAR
View PDF59 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0010] In view of the foregoing, coatings for reducing the rate of release a therapeutic substance from implantabl

Problems solved by technology

A problem associated with the above procedure includes formation of intimal flaps or torn arterial linings which can collapse and occlude the conduit after the balloon is deflat

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Stent with coatings containing self-assembled monolayers
  • Stent with coatings containing self-assembled monolayers
  • Stent with coatings containing self-assembled monolayers

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0059] A first composition can be prepared by mixing the following components:

[0060] (a) about 0.4 g of PBMA-HEMA, having a number average molecular weight of about 207,000 and a weight average molecular weight of about 378,000, with the molar ratio between the butylmethacrylate-derived units and the hydrbxyethyl methacrylate-derived units of about 3:1;

[0061] (b) about 11.568 g of acetone;

[0062] (c) about 7.712 g of xylene; and

[0063] (d) about 0.32 g of EVEROLIMUS.

[0064] The first composition can be applied onto the surface of a 13 mm TETRA stent (available from Guidant Corp.) by spraying and dried to form a drug-polymer layer. A spray coater having an EFD 7803 spray valve with 0.014 inch fan nozzle with a VALVEMATE 7040 control system, manufactured by EFD, Inc. of East Providence, R.I. can be used. The feed pressure can be about 0.2 atm (about 3 psi) and an atomization pressure can be about 1.35 atm (about 20 psi). The drug-polymer layer can be baked at about 80° C. for about ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Therapeuticaaaaaaaaaa
Biocompatibilityaaaaaaaaaa
Login to view more

Abstract

A medical device with a coating, particularly a drug eluting stent, is described. The coating includes a self-assembled monolayer.

Description

CROSS REFERENCE [0001] This is a divisional application of U.S. Ser. No. 10 / 255,911, which was filed on Sep. 26, 2002.BACKGROUND [0002] 1. Field of the Invention [0003] This invention is directed to coatings for implantable medical devices, such as drug eluting vascular stents. [0004] 2. Description of the State of the Related Art [0005] Percutaneous transluminal coronary angioplasty (PTCA) is a procedure for treating heart disease. A catheter assembly having a balloon portion is introduced percutaneously into the cardiovascular system of a patient via the brachial or femoral artery. The catheter assembly is advanced through the coronary vasculature until the balloon portion is positioned across the occlusive lesion. Once in position across the lesion, the balloon is inflated to a predetermined size to radially compress against the atherosclerotic plaque of the lesion to remodel the lumen wall. The balloon is then deflated to a smaller profile to allow the catheter to be withdrawn f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4745A61F2/00
CPCA61K31/4745A61L31/10A61L31/16Y10T428/24B82Y30/00B82Y40/00A61L2300/416
Inventor DING, NI
Owner ABBOTT CARDIOVASCULAR
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap